Phase II Study of Bevacizumab and Doxil in the Treatment of Platinum-Resistant or Refractory Ovarian Cancer
Avastin is a humanized monoclonal antibody (a type of protein that is normally made by the
immune system to help defend the body from infection and cancer). Avastin has been approved
for the treatment of colorectal cancer and lung cancer. Avastin is investigational for the
treatment of ovarian cancer and has not been approved by the United States Food and Drug
Administration (FDA) for this use.
Avastin is thought to work by attaching to a protein called vascular endothelial growth
factor (VEGF) to block its action. VEGF plays a role in the formation of both normal and
abnormal blood vessels. It is present in normal tissues, but is produced in excess by most
solid cancers (tumors). In cancer, VEGF helps blood vessels bring nutrients to tumor cells,
allowing the tumor cells to grow. In laboratory studies with human cancer cells grown in
animals, Avastin has been shown to prevent or slow the growth of different types of cancer
cells by blocking the effects of VEGF.
Doxorubicin is a type of antibiotic that is only used in cancer chemotherapy. It slows or
stops the growth of cancer. Doxorubicin has been approved by the FDA to treat cancers of
the head, neck, cervix, vagina, testes, prostate, uterus and Ewing's tumor.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression Free Survival (PFS) is the primary outcome measure
Claire F. Verschraegen, M.D.
University of New Mexico
United States: Food and Drug Administration
|New Mexico Cancer Care Associates||Santa Fe, New Mexico 87505-7670|
|University of New Mexico||Albuquerque, New Mexico 87131|
|New York University Cancer Institute||New York, New York 10016|